Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis

American Journal of Cardiology

Volumn 90, Issue 9, 2002, Pages 959-963

  Whelton, Andrew ^a,g   White, William B ^b   Bello, Alfonso E ^c   Puma, Joseph A ^d,e   Fort, John G ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c ILLINOIS BONE AND JOINT INSTITUTE   (United States)

^d Heart and Vascular Center   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f PFIZER INC   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ROFECOXIB;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEIGHT GAIN;

AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG EVALUATION; EDEMA; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; LACTONES; MALE; NORTH AMERICA; OSTEOARTHRITIS; PYRAZOLES; SULFONAMIDES; SULFONES; SYSTOLE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0036830135     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02661-9     Document Type: Article

References (23)

1. Pope J.E., Anderson J.J., Felson D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 153:1993;477-484.
2. Johnson A.G., Nguyen T.V., Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 121:1994;289-300.
3. Morgan T.O., Anderson A., Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens. 13:2000;1161-1167.
4. Chawla P.S., Kochar M.S. Effect of pain and nonsteroidal analgesics on blood pressure. Wisconsin Med J. 98:1999;22-25. 29.
5. Fricker A.F., Nussberger J., Meilenbrock S., Brunner H.R., Burnier M. Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Kidney Int. 54:1998;2089-2097.
6. Polonia J., Boaventura I., Gama G., Camoes I., Bernardo F., Andrade P., Nunes J.P., Brandao F., Cerqueira-Gomes M. Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens. 13:1995;925-931.
7. Whelton A., Maurath C.J., Verburg K.M., Geis G.S. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 7:2000;159-175.
8. Whelton A., Schulman G., Wallemark C., Drower E.J., Isakson P.C., Verburg K.M., Geis G.S. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 160:2000;1465-1470.
9. Vioxx. Package insert. Whitehouse Station, NJ. Merck & Co., Inc., April 2002.
10. Celebrex. Package insert. Skokie, IL. Searle & Co., Inc., October 2001.
11. Whelton A., Fort J.G., Puma J.A., Normandin D., Bello A.E., Verburg K.M. Cyclooxygenase-2-specific inhibitors and cardiorenal function a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients . Am J Ther. 8:2001;85-95.
12. Rossat J., Maillard M., Nussberger J., Brunner H.R., Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 66:1999;76-84.
13. White W.B., Faich G., Whelton A., Maurath C., Ridge N.J., Verburg K.M., Geis G.S., Lefkowith J.B. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 89:2002;425-430.
14. Physician Drug, Diagnosis Audit (PDDA), Scott-Levin, Inc., Available at: http://www.quintiles.com/productsandservices/informatics/scottlevin/ productsandservices/marketing audits/pdda. 2000.
15. White W., Kent J., Taylor A., Verburg K., Lefkowith J., Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 39:2002;929-934.
16. FDA Advisory Committee Background Information. Cardiovascular-Renal Safety Review (VIGOR), by Merck Research Laboratories, Rofecoxib NDA 21-042. pp. 57-59. Avaliable at URL: http://www.fda.gov/ohrms/dockets/ac/cder01.htm#Arthritis. Accessed February 8, 2001.
17. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 343:2000;1520-1528.
18. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-1255.
19. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286:2001;954-959.
20. Vane J.R. Biomedicine. Back to an aspirin a day? Science. 296:2002;474-475.
21. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 345:2001;433-442.
22. Dalen J.E. Selective COX-2 inhibitors, NSAIDs, aspirin, and myocardial infarction. Arch Intern Med. 162:2002;1091-1092.
23. Arthritis Advisory Committee - FDA Briefing Information, NDA 21-042/S007, Vioxx (Rofecoxib). FDA Medical Officer's Cardiovascular Review, pp 22-23. Avaliable at URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf. Accessed February 8, 2001.